Lansoprazole
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318087

CAS#: 103577-45-3

Description: Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole which inhibits the stomach's production of gastric acids. As of 2015, laboratory studies were underway on analogs of lansoprazole to explore their use as potential PET imaging agents for diagnosing tauopathies including Alzheimer's disease. Lansoprazole is also a prodrug that targets the cytochrome bc1 complex of Mycobacterium tuberculosis once converted to lansoprazole sulfide in mycobacterial host cells.


Price and Availability

Size
Price

1g
USD 295
10g
Ask price
Size
Price

2g
USD 495
20g
Ask price
Size
Price

5g
USD 1200

Lansoprazole, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318087
Name: Lansoprazole
CAS#: 103577-45-3
Chemical Formula: C16H14F3N3O2S
Exact Mass: 369.0759
Molecular Weight: 369.3615
Elemental Analysis: C, 52.03; H, 3.82; F, 15.43; N, 11.38; O, 8.66; S, 8.68


Synonym: Lansoprazole, AG-1749, Prevacid, Zoton, Agopton, Bamalite, Opiren

IUPAC/Chemical Name: 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole

InChi Key: MJIHNNLFOKEZEW-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

SMILES Code: O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Satoh H. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. Curr Pharm Des. 2013;19(1):67-75. Review. PubMed PMID: 22950496.

2: Capurso G, Marignani M, Attilia F, Milione M, Colarossi C, Zampaletta C, Di Giulio E, Delle Fave G. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. Dig Liver Dis. 2011 May;43(5):380-5. doi: 10.1016/j.dld.2010.11.015. Epub 2010 Dec 30. Review. PubMed PMID: 21195042.

3: Miura M. Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi. 2006 Jun;126(6):395-402. Review. PubMed PMID: 16755125.

4: Asano M, Taniwaki H, Tsuji D, Sato Y, Shimizu T. [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy]. Nihon Rinsho. 2005 Dec;63 Suppl 12:450-3. Review. Japanese. PubMed PMID: 16416832.

5: Fukuda Y, Tomita T, Koizuka H, Aoyama N. [Recent topics on important drugs for H. pylori eradication: Lansoprazole]. Nihon Rinsho. 2005 Nov;63 Suppl 11:338-49. Review. Japanese. PubMed PMID: 16363557.

6: Croom KF, Scott LJ. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. Drugs. 2005;65(15):2129-35; discussion 2136-7. Review. PubMed PMID: 16225368.

7: Dando TM, Plosker GL. Intravenous lansoprazole: in erosive oesophagitis. Drugs. 2004;64(18):2085-9; discussion 2090. Review. PubMed PMID: 15341501.

8: Curran MP, Wellington K. Delayed-release lansoprazole plus naproxen. Drugs. 2004;64(17):1915-9; discussion 1920-1. Review. PubMed PMID: 15329041.

9: Sugiyama T, Asaka M. [Eradication effect of lansoprazole-based triple therapy against H. pylori]. Nihon Rinsho. 2004 Mar;62(3):483-8. Review. Japanese. PubMed PMID: 15038091.

10: Raghunath AS, Green JR, Edwards SJ. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis. Clin Ther. 2003 Jul;25(7):2088-101. Review. PubMed PMID: 12946553.

11: Scott LJ. Lansoprazole: in the management of gastroesophageal reflux disease in children. Paediatr Drugs. 2003;5(1):57-61; discussion 62. Review. PubMed PMID: 12513106.

12: Dobrilla G, Capurso L. [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. Recenti Prog Med. 2000 Apr;91(4):191-210. Review. Italian. PubMed PMID: 10804753.

13: Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):52-62; quiz 121-3. Review. PubMed PMID: 10665250.

14: Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm. 1999 Dec 1;56(23 Suppl 4):S18-21. Review. Erratum in: Am J Health Syst Pharm 2000 Apr 1;57(7):699. PubMed PMID: 10597120.

15: Gisbert JP. [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. Rev Esp Enferm Dig. 1999 Feb;91(2):133-43. Review. Spanish. PubMed PMID: 10231305.

16: Müller P, Simon B. [Helicobacter pylori eradication: modified triple therapy with lansoprazole]. Fortschr Med. 1996 Dec 20;114(35-36):497-9. Review. German. PubMed PMID: 9119351.

17: Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm. 1996 Jun 15;53(12):1401-15. Review. PubMed PMID: 8781686.

18: Lamouliatte H. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies. J Clin Gastroenterol. 1995;20 Suppl 1:S28-31. Review. PubMed PMID: 7673611.

19: Lockhart SP. Clinical review of lansoprazole. Br J Clin Pract Suppl. 1994 May-Jun;75:48-55; discussion 56-7. Review. PubMed PMID: 8060802.

20: Tamura K, Murai M, Tanaka M, Kawano S. [Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy]. Nihon Rinsho. 1993 Dec;51(12):3261-6. Review. Japanese. PubMed PMID: 8283644.